Optum venture arm backs molecular tech platform

Listen

Optum Ventures, the independent investment fund of UnitedHealth Group's Optum, has funneled an undisclosed amount of funding into Scipher Medicine, a startup developing molecular diagnostic technology.

The new financial support comes shortly after Scipher closed its Series B funding round, which brought its total amount raised to $30 million. Optum Ventures' equity investment marks a second close of the Series B round, and will be used to accelerate and expand Scipher's technology to treat more diseases, per a Feb. 19 news release.

Scipher's platform uses artificial intelligence and molecular diagnostic technology to recommend to physicians the most effective treatment based on a patient's individual biology. The platform is currently focused on treating autoimmune conditions.

More articles on health IT:
WHO joins TikTok to battle coronavirus misinformation
Walgreens warns mobile app users that personal data may have been leaked
Hawaii health system notifies 2,900 patients of email mix-up

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Whitepapers

Featured Webinars